Skip to content

Study · Non-randomized trial · 2019

2 results

Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.

Giorgino F, Yu M, Haupt A, Milicevic Z, García-Pérez LE

Diabetes, obesity & metabolism16 Aug 2019Cited by 12 (Europe PMC)

PMID31364266 (opens in a new tab)PMCIDPMC6852007 (opens in a new tab)DOI10.1111/dom.13844 (opens in a new tab)PepBankPUB-31364266
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In T2D patients, dulaglutide reduced HbA1c more than glargine across glycaemic subgroups except low FG/high PPG.

    In plain wordsIn T2D patients, dulaglutide reduced HbA1c more than glargine except in the low fasting glucose/high post-meal glucose subgroup.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c reduction
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.5 mg · 52 weeksAs given in this study (human).

    Source sentences

    Summary
    Greater HbA1c reductions were observed with dulaglutide 1.5 mg compared to glargine in all subgroups (all P ≤ .05), except in the low FG/high PPG subgroup.
    3 context sentences
    Summary · context
    The aim of the present post hoc analysis of the phase 3 AWARD-2 trial was to investigate whether specific baseline glycaemic patterns respond differentially to dulaglutide compared to insulin glargine (glargine).
    Summary · context
    We categorized participants into four subgroups based on prespecified glucose thresholds and their baseline FG and daily 2-hour mean PPG: low FG/low PPG; low FG/high PPG; high FG/low PPG; and high FG/high PPG.
    Summary · context
    Changes in glycaemic measures in response to treatment with dulaglutide or glargine were evaluated in each subgroup.

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 02HumanNot a test of Dulaglutide (Trulicity) aloneNon-randomized trialEfficacy outcome

    In T2D patients, HbA1c fell in all dulaglutide subgroups and all glargine subgroups except low FG/low PPG.

    In plain wordsIn T2D patients, HbA1c fell in all dulaglutide subgroups and all glargine subgroups except low fasting and post-meal glucose.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c reduction
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    At 52 weeks, significant reductions from baseline in glycated haemoglobin (HbA1c) were observed in all subgroups with dulaglutide 1.5 mg and with glargine (all P < .05), except in patients with low FG/low PPG who received glargine.
    3 context sentences
    Summary · context
    The aim of the present post hoc analysis of the phase 3 AWARD-2 trial was to investigate whether specific baseline glycaemic patterns respond differentially to dulaglutide compared to insulin glargine (glargine).
    Summary · context
    We categorized participants into four subgroups based on prespecified glucose thresholds and their baseline FG and daily 2-hour mean PPG: low FG/low PPG; low FG/high PPG; high FG/low PPG; and high FG/high PPG.
    Summary · context
    Changes in glycaemic measures in response to treatment with dulaglutide or glargine were evaluated in each subgroup.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.